Who
Alison L. Hannah
EVP, Chief Medical Officer
Company insider
Files Form 4 as: EVP, Chief Medical Officer, Rigel Pharmaceuticals; Director, NeoGenomics; Chief Medical Officer, CytomX Therapeutics.
In numbers
- Trades disclosed
- 63
- Buys
- 2
- Sells
- 1
- Bought
- $253K
- Sold
- $7,955
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 15 Jul 2015
- Last trade
- 8 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jul 2026filed 10 Jul 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —24,400 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —24,400 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 1 Jun 2025filed 3 Jun 2025 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code M | —12,254 at $0.00 | filing |
| 1 Jun 2025filed 3 Jun 2025 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code A | —16,107 at $0.00 | filing |
| 1 Jun 2025filed 3 Jun 2025 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code A | —23,077 at $0.00 | filing |
| 1 Jun 2025filed 3 Jun 2025 | NEO NeoGenomicsProfessional Services | SEC FORM 4 Code A | —12,254 at $0.00 | filing |
| 1 Jun 2025filed 3 Jun 2025 | NEO NeoGenomicsProfessional Services | SEC FORM 4 Code M | —12,254 at $0.00 | filing |
| 23 May 2025filed 28 May 2025 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 23 May 2025filed 28 May 2025 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 10 Aug 2024filed 13 Aug 2024 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code M | —11,336 at $0.00 | filing |
| 10 Aug 2024filed 13 Aug 2024 | NEO NeoGenomicsProfessional Services | SEC FORM 4 Code M | —11,336 at $0.00 | filing |
| 1 Jun 2024filed 4 Jun 2024 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code A | —8,672 at $0.00 | filing |
| 1 Jun 2024filed 4 Jun 2024 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code A | —12,254 at $0.00 | filing |
| 25 May 2024filed 29 May 2024 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 25 May 2024filed 29 May 2024 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 10 Aug 2023filed 14 Aug 2023 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code A | —8,353 at $0.00 | filing |
| 10 Aug 2023filed 14 Aug 2023 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code A | —11,336 at $0.00 | filing |
| 26 May 2023filed 12 Jul 2023 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
News
NeoGenomics, Inc. (NASDAQ:NEO) Stock Has Average Target Price of $17.67NEO · tickerreport.com · 9 Oct 2026
0 headlines in the last 90 days name Alison L. Hannah; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.